Major Depressive Disorder Clinical Trial
Official title:
CSP #556 - The Effectiveness of rTMS in Depressed VA Patients
The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.
Major depression occurs in about 10% of American outpatients every year and of those,
approximately 20% respond incompletely or not at all to trials of antidepressants, mood
stabilizers, or psychotherapy (Kaplan and Sadock, 1996; Keller et al 1992; Thase, 2004).
Treatment as usual for these cases of treatment resistant major depression (TRMD) frequently
involves increased risks and increased side effects, such as those seen in monoamine oxidase
inhibitors (MAOIs) and electroconvulsive therapy (ECT). New TRMD treatments are needed,
preferably without major safety concerns or side effects as seen with aggressive polypharmacy
or ECT.
Repetitive transcranial magnetic stimulation (rTMS) is a method of delivering brain
stimulation without the seizures or risks associated with ECT, nor the potential side effects
and risks of MAOI therapy. Systematic review and meta-analysis of the studies to date, which
are typically of a small scale, appear to show a positive effect in TRMD (Martin et al.
2003). With a minimal side effect profile, and the rarity of untoward events and side-effects
(Pascual-Leone et al. 1993; Wassermann 1997), safety concerns regarding the use of rTMS are
considerably less than with ECT. Given this, rTMS has the potential to be a significant
advance in care, if it were shown to be effective in TRMD in VA patients.
The trials of rTMS performed to date have not included participants with comorbid disorders,
such as substance abuse and post-traumatic stress disorder (PTSD), thus the generalizability
of their findings to a VA population is not clear. Further research including Veterans with
possible comorbid disorders is necessary, given the high rates of co-occurring substance
abuse and PTSD that is present in the Veteran population.
The present study is a randomized, controlled trial that compares active rTMS to a sham
condition in Veterans with treatment resistant major depression and possible comorbid
post-traumatic stress disorder (PTSD) and / or a history of substance abuse. Veterans will
remain under the care of their VA primary mental health provider throughout the project.
Participants will be assessed at pre-, mid- and several post-treatment time points. This is a
multisite trial that will be conducted at 9 VA Medical Centers around the country.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |